Waltz Quoted on Payment Reporting for Drug & Device Makers

12 April 2017 Bloomberg BNA News
Partner Judy Waltz was quoted in a Bloomberg BNA article, “Drug, Device Markers Could Get Hit for Not Reporting Payments to Doctors,” covering the current and future states of the Open Payments program.

Waltz explained that Open Payments reporting “remains an administrative burden for drug and device manufacturers” but “payment reporting is becoming widespread throughout the health-care industry.” She also explained, as it relates to the future of the program, “the Trump administration has spoken about reducing regulatory burdens, and Open Payments could fit under that category.”

Related Services

Insights

Supreme Court Limits Patent Assignor Estoppel
02 August 2021
PharmaPatents
Review of Recent Whistleblower Developments
30 July 2021
Legal News: Whistleblower Developments
$4.24M Now the Average Cost Per Data Breach!
30 July 2021
Internet, IT & e-Discovery Blog
Podcast Episode 56: All Things Summer Associate Recruiting
30 July 2021
Foley Career Perspectives
30th Annual Law of Product Distribution & Franchise Seminar
29 September | 7 & 20 October 2021
Milwaukee | Chicago | Dallas
7th National Telehealth Summit
4-5 October 2021
Miami Beach, FL
AHLA Fraud & Compliance Forum
21-22 September 2021
Baltimore, MD
2nd Clinical Trial Agreements Forum
16-17 September 2021
Online Livestream